ArticleFrontiers in pharmacology2025
Ginsenoside Rg1 controls CKLF1-mediated apoptosis to reduce hypoxic/reoxygenation injury in HT22 cells.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke is a prevalent and debilitating neurodegenerative condition. Ginsenoside Rg1 has demonstrated neuroprotective properties in the context of stroke. The upregulation of chemokine-like factor 1 (CKLF1) observed in ischemic stroke positions CKLF1 as a promising therapeutic target. However, limited research has explored whether Rg1 can mitigate oxygen-glucose deprivation/reoxygenation (OGD/R)-induced apoptosis in HT22 cells through the modulation of CKLF1. Methods: In this study, Na Results: In this study, the optimal parameters for the OGD/R model were determined: 25 mmol/L Na Conclusion: Rg1 attenuates OGD/R injury, reduces oxidative stress and apoptosis in HT22 cells by inhibiting CKLF1 expression and alleviates the inflammatory response in activated BV-2 cells, showing therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.